MedTrace Logo

TGRX-678 Phase I Oral Pharmacokinetic Study

NCT06697899 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2025-05-16

No results posted yet for this study

Summary

A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-678

Conditions

  • Chronic Myeloid Leukemia

Interventions

DRUG

TGRX-678

All participants are given TGRX-678 orally at 240 mg

Sponsors & Collaborators

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • Shenzhen TargetRx, Inc.

    lead INDUSTRY

Principal Investigators

  • Juan Li, MD · Nanjing Drug Tower Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-24
Primary Completion
2025-01-06
Completion
2025-02-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06697899 on ClinicalTrials.gov